The stock of CollPlant Biotechnologies Ltd (CLGN) has gone up by 58.21% for the week, with a 50.00% rise in the past month and a -9.14% drop in the past quarter. The volatility ratio for the week is 39.53%, and the volatility levels for the past 30 days are 17.35% for CLGN. The simple moving average for the past 20 days is 49.19% for CLGN’s stock, with a -13.69% simple moving average for the past 200 days.
Is It Worth Investing in CollPlant Biotechnologies Ltd (NASDAQ: CLGN) Right Now?
Additionally, the 36-month beta value for CLGN is 1.10. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CLGN is 7.68M and currently, short sellers hold a 0.03% ratio of that float. The average trading volume of CLGN on June 02, 2025 was 57.31K shares.
CLGN) stock’s latest price update
The stock of CollPlant Biotechnologies Ltd (NASDAQ: CLGN) has decreased by -29.96 when compared to last closing price of 4.54.Despite this, the company has seen a gain of 58.21% in its stock price over the last five trading days. prnewswire.com reported 2025-05-30 that REHOVOT, Israel, May 30, 2025 /PRNewswire/ — CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,200,002 of the Company’s ordinary shares at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered to purchase up to 1,200,002 of the Company’s ordinary shares at an exercise price of $3.00 per share.
Analysts’ Opinion of CLGN
Many brokerage firms have already submitted their reports for CLGN stocks, with Alliance Global Partners repeating the rating for CLGN by listing it as a “Buy.” The predicted price for CLGN in the upcoming period, according to Alliance Global Partners is $22.75 based on the research report published on February 17, 2023 of the previous year 2023.
CLGN Trading at 35.98% from the 50-Day Moving Average
After a stumble in the market that brought CLGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.52% of loss for the given period.
Volatility was left at 17.35%, however, over the last 30 days, the volatility rate increased by 39.53%, as shares surge +45.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.98% upper at present.
During the last 5 trading sessions, CLGN rose by +58.21%, which changed the moving average for the period of 200-days by -31.17% in comparison to the 20-day moving average, which settled at $2.13. In addition, CollPlant Biotechnologies Ltd saw -11.67% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CLGN
Current profitability levels for the company are sitting at:
- -33.5 for the present operating margin
- -2.7 for the gross margin
The net margin for CollPlant Biotechnologies Ltd stands at -32.25. The total capital return value is set at -1.1. Equity return is now at value -75.27, with -58.38 for asset returns.
Based on CollPlant Biotechnologies Ltd (CLGN), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -4.57. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is -1014.76.
Currently, EBITDA for the company is -16.21 million with net debt to EBITDA at 0.54. When we switch over and look at the enterprise to sales, we see a ratio of 53.59. The receivables turnover for the company is 0.88for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.48.
Conclusion
In conclusion, CollPlant Biotechnologies Ltd (CLGN) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
